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ABSTRACT  
  
	  Serotonin (5-HT) and the 5-HT1A receptor during development are known to modulate 
anxiety and depression in later life. However, the brain mechanisms linking the postnatal 
5-HT system and adult behavior remain unknown. Here, we examined the effects of 
pharmacological 5-HT1A receptor activation during the postnatal period on anxiety and 
depression-like behavior in adult BALB/c male mice. To elucidate the underlying 
mechanisms, we measured mRNA expression of the 5-HT1A receptor, brain-derived 
neurotrophic factor (BDNF), GABAA receptor subunits, and AMPA receptor subunits in the 
medial prefrontal cortex (mPFC), amygdala, and hippocampus. Treatment with the selective 
5-HT reuptake inhibitor (fluoxetine) and 5-HT1A receptor agonist (8-OH-DPAT) during the 
postnatal period decreased anxiety-like behavior in adulthood, whereas only 8-OH-DPAT 
treatment increased depression-like behavior. Concomitantly with the behavioral effects, 
postnatal treatment with fluoxetine and 8-OH-DPAT decreased the mRNA expression of the 
GABAA receptor α3 subunit in the mPFC and ventral hippocampus in adulthood, while 
8-OH-DPAT, but not fluoxetine, decreased the mRNA expression of the 5-HT1A receptor and 
BDNF in the mPFC and the GABAA receptor α2 subunit in the mPFC and ventral 
hippocampus. On the basis of the correlative changes between behavior and mRNA 
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expression, these results suggest that the GABAA receptor α3 subunit in the mPFC and 
ventral hippocampus may regulate anxiety-like behavior. In contrast, depression-like 
behavior may be regulated by the 5-HT1A receptor and BDNF in the mPFC and by the 
GABAA receptor α2 subunit in the mPFC and ventral hippocampus. In summary, activation 
of the 5-HT1A receptor during the postnatal period may reduce anxiety levels, but increase 
depression levels during adulthood via different multiple molecules in the mPFC and ventral 
hippocampus. 
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1. Introduction 
 
  Early-life experiences are known to alter brain development and behaviors in later life. For 
example, many studies have shown that prolonged maternal separation during the postnatal 
period increases both anxiety and depression levels in adulthood and impairs brain 
development including hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and 
low neurotrophin levels (Nishi et al., 2014; Tractenberg et al., 2016). In addition, early-life 
chronic stress induces disabilities in learning and memory in adulthood together with 
structural changes, including loss of dendrites, dendritic spines, and excitatory synapses 
(McClelland et al., 2011). In contrast to early-life adverse experiences, postnatal brief 
maternal separation reduces anxiety-like behavior and enhances spatial learning and memory 
in adulthood, which is accompanied by lower HPA axis responsiveness (Nishi et al., 2014; 
Raineki et al., 2014). Thus, alterations in brain structures and functions may cause behavioral 
changes in later life. However, the brain mechanisms (molecules and brain regions), that link 
early-life experiences to behavioral changes in later lifer are not well known. 
  Serotonin (5-hydroxytryptamine; 5-HT) regulates various brain functions, and malfunction 
of the 5-HT system during development is closely related to mood disorders in adulthood 
(Daubert and Condron, 2010). In addition to effects on behavior, 5-HT has neurotrophic 
activity during development to regulate the formation of neural circuits (Whitaker-Azmitia, 
2001). Thus, the roles of 5-HT during development are important for the development of 
brain and behavior. 
  There are at least 14 5-HT receptors, among which the 5-HT1A receptor is well 
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characterized. Similar to the action of 5-HT, the 5-HT1A receptor modulates dendrite 
formation and synaptogenesis (Wilson et al., 1998; Yoshida et al., 2011; Mogha et al., 2012) 
and affects behavior in later life. Interestingly, previous studies suggested that the 5-HT1A 
receptor during the postnatal period has different effects on anxiety and depression-like 
behavior in adulthood. By use of conditional knockout of the 5-HT1A receptor and treatment 
with a 5-HT1A receptor antagonist, it has been shown that blockade of the 5-HT1A receptor 
during the postnatal period increases anxiety-like behavior in adulthood (Gross et al., 2002; 
Vinkers et al., 2010). In contrast, blockade of the 5-HT1A receptor during the postnatal period 
normalizes depression-like behavior in adult 5-HT transporter knockout mice (Alexandre et 
al., 2006). However, the brain mechanisms linking the 5-HT1A receptor during the postnatal 
period to anxiety or depression in adulthood are not known.  
  One of the candidate molecules regulating anxiety in response to 5-HT is the GABAA 
receptor. The GABAA receptor is a target of benzodiazepines, anxiolytics. Benzodiazepines 
have acute effects in the treatment of generalized anxiety disorder, social anxiety disorder, 
and panic disorder (Griebel and Holmes, 2013), whereas selective 5-HT reuptake inhibitors 
(SSRIs) show their effects after several weeks of treatment (Vaswani et al., 2003). Among 
the 19 GABAA receptor subunits, the α2 and α3 subunits modulate anxiety-like behavior. The 
diazepam-induced anxiolytic effect is absent in mice with point mutation of the α2 subunit, 
suggesting that the α2 subunit has an anxiolytic effect (Low et al., 2000). In addition, the 
selective agonist for the α3 subunit shows an anxiolytic effect (Dias et al., 2005) and the α3 
subunit inverse agonist shows an anxiogenic effect in rats (Attack et al., 2005).  
  On the other hand, brain-derived neurotrophic factor (BDNF) and the glutamate receptor 
have been shown to be involved in depression. Similar to 5-HT, BDNF contributes to various 
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functions in the developing and mature brain, including survival and differentiation of 
neurons, dendrite formation, synaptogenesis, and synaptic plasticity (Park and Poo, 2013). 
Moreover, dysfunction of BDNF is related to depression (Nestler, 2002). For example, both 
acute and chronic stresses decrease the expression of BDNF in the hippocampus, and 
antidepressants increase the expression of BDNF to recover stress-induced reduction of 
BDNF (Nestler, 2002). 
  Besides the 5-HT system, glutamate receptors are known as a target of antidepressants. 
Recently, it was shown that ketamine has acute antidepressant activity (Murrough, 2012). 
Ketamine shows antidepressant effects in a few hours to several days, whereas SSRI requires 
a few weeks to show antidepressant effects. In addition to NMDA receptor antagonism, 
ketamine potentiates AMPA receptors, which have a crucial role in the antidepressant effect 
(Koike and Chaki, 2014). Most AMPA receptors are composed of the GluR1 and GluR2 
subunits (Derkach et al., 2007), and these subunits are involved in long-term potentiation 
(LTP) and long-term depression (LTD) in synaptic plasticity (Huganir and Nicoll, 2013).  
  In the present study, we first examined the effects of postnatal treatment with SSRI and the 
5-HT1A receptor agonist on adult behaviors such as anxiety and depression. Next, to elucidate 
the underlying brain mechanisms of anxiety and depression, we measured the mRNA 
expression of the 5-HT1A receptor, BDNF, the GABAA receptor α2 and α3 subunits, and the 
AMPA GluR1, and GluR2 subunits in the mPFC, amygdala, and dorsal and ventral 
hippocampi during the postnatal period and adulthood. By comparing the changes in 
behaviors with those in the mRNA expressions induced by SSRI and the 5-HT1A receptor 
agonist, we found some candidate genes, that may regulate adult behaviors.  
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2. Materials and methods 
 
2.1. Animals 
  Pregnant female BALB/c mice (Japan SLC Inc., Shizuoka, Japan) were individually 
housed and maintained under a 12:12 h light/dark cycle (lights on 8:00AM) at 24oC, with 
food and water available ad libitum. The date of birth was considered as postnatal day 0 (P0). 
Only male offspring were used. All the experiments were conducted in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the National Institutes of 
Health (USA) and were approved by the Animal Experimentation Committee of the 
University of Tsukuba. 
 
2.2. Drug treatment 
  Offspring were randomly assigned to 3 groups; control group, treatment with the selective 
5-HT reuptake inhibitor (SSRI) group, and treatment with the 5-HT1A receptor agonist group. 
Pups from each group received an oral administration of 5% sucrose (control), 5 mg/kg 
fluoxetine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) (SSRI), or 5 mg/kg 
(R)-(+)-8-hydroxy-DPAT hydrobromide (8-OH-DPAT) (Sigma-Aldrich) (5-HT1A receptor 
agonist), using a pipettor (Pipetman, Gilson, Middleton, WI, USA) with a small tip at its end, 
from P1 to P21. The dose was decided on the basis of a previous study (Ishiwata et al., 2005). 
 
2.3. Elevated plus maze (EPM) 
  All behavioral tests were conducted from postnatal week 9 to 10. To investigate the effects 
on anxiety-like behavior, the offspring of each experimental group were tested using the 
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EPM (Ohara & Co., Ltd., Tokyo, Japan). The apparatus was elevated 60 cm from the floor 
and consisted of two opposing open arms (25 cm length x 5 cm width x 0.3 cm height) and 
two opposing closed arms (25 cm x 5 cm x 15 cm) that were connected by a central platform 
(6 cm x 6 cm). Each animal was placed in the central platform, facing a closed arm. All 
animals were tested once between 10:00 and 13:00, under regular room light (360 lux). The 
behavior was recorded for 5 min by use of an overhead color CCD camera. The time spent in 
the open arms and the number of entries into the open arms were calculated as indices of 
anxiety-like behavior.  
    
2.4. Forced swim test (FST) 
  Depression-like behavior was assessed as previously described (Porsolt et al., 1977) with 
slight modifications. The offspring of each experimental group were tested using the FST. All 
animals were tested between 12:00 and 14:00, under regular room light (360 lux). Each 
animal was placed into the water (23 ± 1 oC) (7-cm height) in a 4L beaker (20-cm diameter). 
The behavior was analyzed during the last 4 min of the 6-min testing period. The first 2 min 
were considered as habituation. The time spent floating on the water surface without any 
movement except for minimal activity that the mouse kept them from drowning was 
measured as an index of depression-like behavior. The time spent climbing was recorded 
when vigorous vertical movements with the forepaws against the wall of the beaker were 
displayed. Swimming time was calculated by subtracting the floating and the climbing times 
from the total testing period. 
 
2.5. Sucrose preference test (SPT) 
 9 
  For the SPT, the offspring were acclimatized to two identical drinking bottles, one filled 
with 2% sucrose solution and the other with water, for 4 hr/day for 4 days. After overnight 
water deprivation, the SPT was conducted for 4 hr on the day 5. To avoid the side preference, 
the positions of the bottles were switched after 2 hr and interchanged daily. Sucrose and 
water consumption were determined by measuring the change in the volume of fluid 
consumed. Sucrose preference was defined as the ratio of the volume of sucrose versus the 
total volume of sucrose and water consumed during the 4-hr test. 
 
2.6. Brain dissection 
  Under anesthesia by isoflurane, the mice were decapitated and their brains were quickly 
removed at P22 and P71. 2 mm thick coronal slices were cut on ice from the frontal pole of 
the cerebral cortex using a Mouse Brain Matrix (Muromachi Kikai Co., Ltd., Tokyo, Japan), 
and the left hemisphere was used for the analysis of the expression of mRNA. The mPFC 
(Leuner and Shors, 2013) was punched out from the first slice and the amygdala was punched 
out from the third slice using a Harris Micro-Punch (GE healthcare, Buckinghamshir, UK) 
(Supplemental Fig. S1). The dorsal and ventral halves of the hippocampus were dissected out 
using a Noyes surgical scissor. We divided the hippocampus into dorsal and ventral halves 
because these regions have been shown to be involved in cognition and emotion, respectively 
(Bannerman et al., 2004). 
 
2.7. Real-time reverse transcription-PCR 
  Real-time reverse transcription-PCR was performed as previously described (Akatsu et al., 
2015). In brief, each region of the left hemisphere was homogenized in RNAiso (Takara Bio, 
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Shiga, Japan) and total RNA was isolated using RNAiso (Takara Bio), according to the 
manufacturer’s instructions. The isolated 1 µg of total RNA was reverse-transcribed using the 
QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany). PCR was performed using 
the Thermal Cycler Dice Real Time TP800 System (Takara Bio) with SYBR Premix Ex Taq 
II (Takara Bio). The thermal cycling conditions comprised an initial step at 95℃ for 10 sec, 
followed by 50 cycles at 95℃ for 5 sec and at 60℃ for 30 sec. Table 1 lists the primer 
sequences. The BDNF, GluR1, and GluR2 genes have splicing variants. The primers we used 
are designed to capture all the splicing variants. The 5-HT1A receptor, GABAA receptor α2 
and α3 subunits, and 18S rRNA genes do not have any splicing variants. The sizes of the 
PCR products were verified using agarose gel electrophoresis. Quantitation was performed 
using the crossing point method. The data was normalized to 18S rRNA. 
 
2.8. Statistical analysis 
  Using SPSS (IBM, Armonk, NY, USA), the data were analyzed using one-way analysis of 
variance (ANOVA), followed by a post hoc test (Tukey or Bonferroni). p < 0.05 was 
considered as statistically significant. All data are expressed as means ± S.E.M. 
 
3. Results 
 
3.1. Postnatal treatment with fluoxetine and 8-OH-DPAT did not alter body weight 
  During the drug treatment from P1 to P21, the main-day effect on body weight was 
significant (F(20,1960) = 2624.008, p < 0.001), but the interaction between day and group 
was not significant (Supplemental Table 1). Thus, the drug treatment had no effect on the 
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body weight. 
 
3.2. Postnatal treatment with fluoxetine and 8-OH-DPAT decreased anxiety-like behavior in 
the adulthood 
  We used the EPM to examine the effects of postnatal treatment with fluoxetine and 
8-OH-DPAT on anxiety-like behavior in adulthood (Fig. 1). ANOVA revealed significant 
main effects on the time spent in open arms (F(2,38) = 8.788, p < 0.001) (Fig. 1A), the ratios 
of entries into open arms (F(2,38) = 9.152, p < 0.001) (Fig. 1B), and the total number of 
entries into both open and closed arms (F(2,38) = 4.104, p < 0.05) (Fig. 1C). The post hoc 
test showed that postnatal treatment with both fluoxetine and 8-OH-DPAT increased the time 
spent in open arms (fluoxetine, p < 0.05; 8-OH-DPAT, p < 0.01) (Fig. 1A) and the entries 
into open arms (fluoxetine, p < 0.01; 8-OH-DPAT, p < 0.01) (Fig. 1B), as compared with the 
control mice. In addition, postnatal 8-OH-DPAT treatment decreased the total number of 
entries into both open and closed arms (p < 0.05), whereas fluoxetine treatment had no effect 
as compared with the control mice (Fig. 1C). Thus, these results suggest that treatment with 
fluoxetine and 8-OH-DPAT during the postnatal period decreased anxiety-like behavior in 
adulthood. 
 
3.3. Postnatal treatment with 8-OH-DPAT increased depression-like behavior in adulthood 
  We used the FST (Fig.2 ) and the SPT (Fig. 3) to examine the effects of postnatal treatment 
with fluoxetine and 8-OH-DPAT on adult depression-like behavior. According to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V), major depressive disorder 
in humans is defined by depressed mood (behavioral despair) or a loss of interest or pleasure 
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(anhedonia) in daily activities. Therefore, we used the FST to measure behavioral despair 
(Porsolt et al., 2001) and the SPT to measure anhedonia (Papp et al., 1991).  
  In the FST, ANOVA revealed significant main effects on the floating (F(2,37) = 5.069, p < 
0.05) (Fig. 2A), swimming (F(2,37) = 6.841, p < 0.01) (Fig. 2B), and climbing (F(2,37) = 
4.851, p < 0.05) (Fig. 2C) times. Postnatal 8-OH-DPAT treatment increased the floating time 
(p < 0.05) (Fig. 2A), whereas it decreased the swimming (p < 0.05) (Fig. 2B) and climbing (p 
< 0.05) (Fig. 2C) times. Postnatal fluoxetine treatment had no effects on the floating (Fig. 
2A), swimming (Fig. 2B), and climbing (Fig. 2C) times. 
  In the SPT, ANOVA revealed no significant main effect on the sucrose preference (F(2,38) 
= 0.466, p = 0.631) (Fig. 3).  
  Thus, treatment with 8-OH-DPAT but not with fluoxetine during the postnatal period 
increased the the depression-like behavior of behavioral despair in adulthood. 
 
3.4. Postnatal treatment with fluoxetine and 8-OH-DPAT did not affect spatial learning and 
memory and pain sensitivity in the adulthood 
  We also examined the effects of postnatal fluoxetine and 8-OH-DPAT on adult spatial 
learning and memory and pain sensitivity in adulthood (Supplemental Figs. S2-S4). In the 5 
day-training of MWM, the main-day effects were significant (fluoxetine, F(4,52) = 13.065, p 
< 0.001; 8-OH-DPAT, F(4,76) = 18.435, p < 0.001), but the interactions between day and 
group were not significant (Supplemental Figs. S2A, S3A). The probe test showed no 
significant effects on the time spent in the platform quadrant and the number of crossings of 
the platform (Supplemental Figs. S2B, S3B). The cued test also showed no significant effects 
(Supplemental Figs. S2C, S3C). 
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  In the hot plate test, neither postnatal fluoxetine nor 8-OH-DPAT affected the reaction 
time (Supplemental Fig. S4). 
 
3.5. Postnatal treatment with 8-OH-DPAT decreased the mRNA expression of the 5-HT1A 
receptor in the mPFC and the reduction was maintained in adulthood  
  We measured the mRNA expression of the 5-HT1A receptor at P22 and P71 to examine the 
chronic effects of fluoxetine and 8-OH-DPAT (Fig. 4). ANOVA revealed significant main 
effects on the mRNA expression of the 5-HT1A receptor at P22 in the mPFC (F(2,23) = 4.228, 
p < 0.05), the dorsal hippocampus (F(2, 22) = 6.061, p < 0.01), and the ventral hippocampus 
(F(2,23) = 5.017, p < 0.05), but not in the amygdala. The treatment with fluoxetine and 
8-OH-DPAT between P1 and P21 decreased the mRNA expression of the 5-HT1A receptor in 
the mPFC (p < 0.05). The treatment with 8-OH-DPAT also decreased the mRNA expression 
of the 5-HT1A receptor in the dorsal hippocampus (p < 0.01) and the ventral hippocampus (p 
< 0.05) at P22 (Fig. 4A).  
  In contrast, ANOVA revealed a significant main effect on the mRNA expression of the 
5-HT1A receptor at P71 in the mPFC (F(2,20) = 5.369, p < 0.05), but not in the amygdala or 
the hippocampus. The treatment with 8-OH-DPAT decreased the mRNA expression of the 
5-HT1A receptor in the mPFC (p < 0.05) (Fig. 4B). These results suggest that the effect of 
postnatal treatment with 8-OH-DPAT on the mRNA expression of the 5-HT1A receptor in the 
mPFC is maintained in adulthood.   
 
3.6. Postnatal treatment with 8-OH-DPAT decreased the mRNA expression of BDNF in the 
adult mPFC 
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  Next, we investigated the mRNA expression of BDNF at P22 and P71 (Fig. 5). ANOVA 
revealed a marginally significant main effect on the mRNA expression of BDNF at P22 in the 
mPFC (F(2,23) = 3.132, p = 0.063), but not in the amygdala or the hippocampus. The 
post-hoc test revealed that the treatments with fluoxetine and 8-OH-DPAT during the 
postnatal period had some tendencies to decrease the mRNA expression of BDNF in the 
mPFC at P22 (fluoxetine, p = 0.11; 8-OH-DPAT, p = 0.082) (Fig. 5A). 
  In contrast, ANOVA revealed a significant main effect on the mRNA expression of BDNF 
at P71 in the mPFC (F(2,23) = 11.411, p < 0.001), but not in the amygdala or the 
hippocampus. The treatment with 8-OH-DPAT during the postnatal period decreased the 
mRNA expression of BDNF in the mPFC at P71 (p < 0.001) (Fig. 5B).  
 
3.7. Postnatal treatment with 8-OH-DPAT decreased the mRNA expression of the GABAA 
receptor α2 subunit in the mPFC and the ventral hippocampus  
  We measured the mRNA expression of the GABAA receptor α2 subunit at P71 (Fig. 6A). 
ANOVA revealed significant main effects on the GABAA receptor α2 subunit in the mPFC 
(F(2,16) = 8.646, p < 0.01), the dorsal hippocampus (F(2,20) = 4.546, p < 0.05), and the 
ventral hippocampus (F(2,17) = 9.782, p < 0.001), but not in the amygdala. The treatment 
with 8-OH-DPAT during the postnatal period decreased the mRNA expression of the 
GABAA receptor α2 subunit in the mPFC and the ventral hippocampus, as compared with the 
control (mPFC, p < 0.01; ventral hippocampus, p < 0.01) and the treatment with fluoxetine 
(mPFC, p < 0.05; ventral hippocampus, p < 0.01). In addition, the treatment with 
8-OH-DPAT during the postnatal period decreased the GABAA receptor α2 subunit in the 
dorsal hippocampus, as compared with the treatment with fluoxetine (p < 0.05). 
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3.8. Postnatal treatment with fluoxetine and 8-OH-DPAT decreased the mRNA expression of 
the GABAA receptor α3 subunit in the mPFC and ventral hippocampus 
  We measured the mRNA expression of the GABAA receptor α3 subunit at P71 (Fig. 6B). 
ANOVA revealed significant main effects in the mPFC (F(2, 23) = 10.996, p < 0.001), 
amygdala (F(2,16) = 6.889, p < 0.01) and ventral hippocampus (F(2,19) = 5.882, p < 0.01), 
but not in the dorsal hippocampus. Both the treatment with fluoxetine and 8-OH-DPAT 
during the postnatal period decreased the GABAA receptor α3 subunit mRNA expression in 
the mPFC (p < 0.01) and ventral hippocampus (p < 0.05). In addition, only the treatment with 
fluoxetine decreased the GABAA receptor α3 subunit mRNA expression in the amygdala (p < 
0.01). 
 
3.9. Postnatal treatment with fluoxetine and 8-OH-DPAT did not affect the mRNA 
expression of GluR1 and GluR2 
  We measured the mRNA expression of GluR1 and GluR2 at P71 as presumptive mediators 
of depression-like behavior (Fig. 7). ANOVA revealed a significant main effect on the 
mRNA expression of GluR1 in the ventral hippocampus (F(2,21) = 3.557, p < 0.05), but not 
in the mPFC or the dorsal hippocampus (Fig. 7A). The treatment with fluoxetine increased 
the mRNA expression of GluR1 in the ventral hippocampus, as compared with the treatment 
with 8-OH-DPAT (p < 0.05). ANOVA revealed no significant main effects on the mRNA 
expression of GluR2 in the mPFC or the dorsal and ventral hippocampi (Fig. 7B).  
 
4. Discussion 
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  Early-life experiences are known to alter brain structures and functions in later life. 
Malfunction of 5-HT and the 5-HT1A receptor during development is closely related to mood 
disorders in adulthood (Daubert and Condron, 2010). The present study showed that 
treatment with fluoxetine and 8-OH-DPAT between P1 and P21 decreased anxiety-like 
behavior in adulthood, while the same 8-OH-DPAT treatment increased the depression-like 
behavior in terms of behavioral despair in adulthood (Supplemental Table 2). To elucidate 
the brain mechanisms that regulate anxiety and depression, we examined the fluoxetine and 
8-OH-DPAT-induced changes in the mRNA expression. Both the treatment with fluoxetine 
and 8-OH-DPAT decreased the mRNA expression of the GABAA receptor α3 subunit in the 
ventral hippocampus. In contrast, only the 8-OH-DPAT treatment decreased the mRNA 
expression of the 5-HT1A receptor and BDNF in the mPFC and the GABAA receptor α2 
subunit in the mPFC and the ventral hippocampus in adulthood (Supplemental Table 3). 
Therefore, we found some correlative changes between adult anxiety and depression and the 
mRNA expression of GABAA receptor α subunits and BDNF in response to postnatal 
treatment with fluoxetine and 8-OH-DPAT. 
	 The present study showed that both fluoxetine and 8-OH-DPAT during the postnatal 
period decreased anxiety-like behavior in adulthood. Therefore, it is possible that among 
5-HT receptors, 5-HT1A receptor may mediate the postnatal SSRI treatment-induced decrease 
in anxiety levels in adulthood. The role of the 5-HT1A receptor in decreasing anxiety is 
consistent with previous studies on postnatal treatment with the 5-HT1A receptor antagonist 
(Vinkers et al., 2010) and 5-HT1A receptor knockout mice (Gross et al., 2002). Both 5-HT1A 
receptor antagonist treatment from P0 to P21 and conditional knockout of the 5-HT1A 
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receptor until P21 increased adult anxiety-like behavior (Gross et al., 2002; Vinkers et al., 
2010). However, there are some discrepancies in the effects of fluoxetine on anxiety-like 
behavior. In the previous studies, early postnatal fluoxetine treatment increased anxiety in 
129/Sv mice (Ansorge et al., 2004 and 2008; Rebello et al., 2014), which is an opposite effect 
to that found in the present study. These differences in the effects of fluoxetine may be 
attributable to strain differences of tryptophan hydroxylase 2 (TPH-2). TPH-2 is the 
rate-limiting enzyme in brain 5-HT synthesis and a single nucleotide polymorphism (SNP) 
was reported in C1473G (Zhang et al., 2004). Depending on the SNP, BALB/c mice show 
reduced synthesis of 5-HT as compared with 129/Sv mice. Fluoxetine treatment of BALB/c 
mice may increase the amount of brain 5-HT suitable for the regulation of anxiety. 
Interestingly, different effects on depression of citalopram, another SSRI, were reported 
between 129/Sv and BALB/c mice: citalopram treatment reduced depression in adult 129/Sv 
mice but did not in BALB/c mice (Cervo et al., 2005). These results suggest that the effects 
of SSRI on anxiety and depression may be dependent on the TPH-2 genotype as well as on 
the period of the treatment. We must be careful to consider the SNP in human TPH-2 
(G1463A) (Zhang et al., 2005), when treating anxiety and mood disorders. 
  In contrast to the effect on anxiety, the present study showed that postnatal 8-OH-DPAT 
treatment increased depression-like behavior. This result confirms that of a previous study 
that blockade of the 5-HT1A receptor during the development alleviates depression-like 
behavior in adulthood (Alexandre et al., 2006). Taken together, these findinfs suggest that the 
activation (or blockade) of the 5-HT1A receptor during the postnatal period decreases (or 
increases) anxiety-like behavior but increases (or decreases) depression-like behavior in 
adulthood. Anxiety and depression are often comorbid, but these findings suggest that these 
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two disorders are caused by different mechanisms (see also Ressler and Nemeroff, 2000; 
Leonardo and Hen, 2008).  
  In the present study, the postnatal treatment with 8-OH-DPAT decreased 5-HT1A receptor 
mRNA expression both in the mPFC and in the hippocampus at P22, but this reduction in 
5-HT1A receptor mRNA expression persisted until P71 in the mPFC, but not in the 
hippocampus. A previous study showed that environmental factors during the perinatal 
period such as prenatal stress and postnatal brief maternal separation (handling) modulated 
the mRNA expression of 5-HT receptors in the offspring’s hippocampus during the postnatal 
period, but not in adulthood, while the effects remained observed in the adult frontal cortex 
(Akatsu et al., 2015). These results suggest that the effects on 5-HT receptor expression are 
maintained in the frontal cortex throughout life, while the hippocampus may have plasticity 
to recover the changes. 
  The present study showed that postnatal treatment with 8-OH-DPAT decreased mRNA 
expression of the 5-HT1A receptor and BDNF in the adult mPFC, and concurrently increased 
depression-like behavior in the adulthood. On the basis of the correlations between the 
mRNA expression and behavior in adulthood, it is be possible that the 5-HT1A receptor and 
BDNF in the adult mPFC may modulate depression-like behavior, which is supported by the 
previous studies (Kato et al, 2015; Sahli et al., 2016). The 5-HT1A receptor is one of the main 
targets for the treatment of major depressive disorder in adult. Kato et al. (2015) reported that 
DSP-1053, a novel SSRI with 5-HT1A receptor agonistic activity shows antidepressant effects 
in adults. In addition, buspirone, 5-HT1A receptor partial agonist, and vilazodone, potent 
SSRI with 5-HT1A receptor partial agonistic activity, have already been approved for clinical 
use, as antidepressants in adults (Sahli et al., 2016). Taken together, the present findings 
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suggest that reduction in 5-HT1A receptor activity in the adult mPFC may increase 
depression-like behavior. In addition, the findings suggest that the 5-HT1A receptor has 
opposite effects on depression between the postnatal period and adulthood. Specifically, the 
activation of the 5-HT1A receptor in adulthood ameliorates depression-like behavior, whereas 
the similar activation of the 5-HT1A receptor during the postnatal period induces 
depression-like behavior in adulthood.  
  Besides the 5-HT1A receptor, many studies including postmortem studies, pharmacological 
studies using antidepressants, and BDNF polymorphism studies have reported strong 
correlations between reduced BDNF signaling in the adult prefrontal cortex and hippocampus 
and depression (Dwivedi, 2009). In addition, functional association between the 5-HT1A 
receptor and BDNF has been suggested. The 5-HT1A receptor is linked to the 
mitogen-activated protein kinase (MAPK) signaling pathway, and the activation of the cyclic 
adenosine monophosphate (cAMP) response element-binding protein (CREB) in the MAPK 
signaling pathway upregulates the expression of BDNF in adulthood (Polter and Li, 2010; 
Homberg et al., 2014). Indeed, the present study showed a positive correlation between the 
mRNA expression of the 5-HT1A receptor and BDNF in the adult mPFC (r = 0.664, p < 
0.001) (Supplemental Fig. S5). Therefore, reduced 5-HT1A receptor in adulthood possibly 
downregulates the expression of BDNF in the mPFC, which may induce depression-like 
behavior.  
  In addition to the 5-HT1A receptor and BDNF, the present study showed that postnatal 
treatment with fluoxetine and 8-OH-DPAT affected the mRNA expression of the GABAA 
receptor α subunits. In particular, 8-OH-DPAT treatment reduced the mRNA expression of 
the GABAA receptor α2 subunits in the adult mPFC and ventral hippocampus. Considering 
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that postnatal 8-OH-DPAT treatment increased adult depression-like behavior, this finding 
suggests that the reduction of GABAA receptor α2 subunits in the adult mPFC and ventral 
hippocampus may be involved in the 8-OH-DPAT-induced increase in depression-like 
behavior. This idea was supported by studies reporting that depression-like behavior is 
increased in GABAA receptor α2 subunit knockout mice (Rudolph and Knoflach, 2011; 
Vollenweider et al., 2011). In addition, the GABAA receptor α2 subunit is involved in adult 
neurogenesis in the dentate gyrus of the hippocampus (Duveau et al., 2011). Since 
antidepressants promote adult neurogenesis (Malberg et al., 2000), it is possible that the 
GABAA receptor α2 subunit in the ventral hippocampus affects depression-like behavior 
through adult neurogenesis.  
  The present study also showed that postnatal treatment with both fluoxetine and 
8-OH-DPAT decreased the mRNA expression of the GABAA receptor α3 subunit in the adult 
mPFC and ventral hippocampus. In addition, both treatments decreased anxiety levels in 
adulthood. On the basis of the correlative changes of mRNA expression and behavior, the 
reduction in the GABAA receptor α3 subunit in the adult mPFC and ventral hippocampus 
may decrease anxiety levels. By treating GABAA receptor α2 subunit mutated mice with the 
GABAA receptor α3 subunit agonist, Dias et al. demonstrated that the GABAA receptor α3 
subunit is more effective in mediating anxiolytic action than is the GABAA receptor α2 
subunit (Dias et al., 2005). However, the changes in the GABAA receptor α3 subunit mRNA 
expression in the ventral hippocampus and anxiety-like behavior in the present study were 
not consistent with those shown in previous studies (Attack et al., 2005; Dias et al., 2005). 
Those studies showed that activation of the GABAA receptor α3 subunit has an anxiolytic 
effect (Dias et al., 2005), whereas suppression of the GABAA receptor α3 subunit has an 
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anxiogenic effect (Attack et al., 2005). This discrepancy between the present and previous 
studies suggests that GABAA receptor α3 subunit in the ventral hippocampus may not play a 
critical role in the anxiolytic effect induced by fluoxetine and 8-OH-DPAT. It is possible that 
activation of the GABAA receptor α3 subunit in brain regions other than that of the ventral 
hippocampus is required for the anxiolytic effect. In addition, in the present study, postnatal 
fluoxetine treatment, but not 8-OH-DPAT treatment, decreased the mRNA expression of the 
GABAA receptor α3 subunit in the amygdala. Therefore, other 5-HT receptors might mediate 
the reduction of the GABAA receptor α3 subunit in the amygdala.  
  The GluR1 and GluR2 subunits of AMPA receptors were reported to modulate depression 
(Martinez-Turrilas et al., 2002; Tan et al., 2006). However, the present study showed no 
significant changes in GluR1 and GluR2 mRNA expression induced by 8-OH-DPAT 
treatment, which increased the depression-like behavior. Therefore, the 5-HT1A receptor 
agonist during the postnatal period may induce depression-like behavior, independently of 
GluR1 or GluR2 expression in the mPFC and the hippocampus. 
 
5. Conclusion 
 
  The present study showed that 5-HT during the postnatal period had an anxiolytic effect in 
adulthood, probably via the 5-HT1A receptor during the postnatal period. In contrast, 
postnatal activation of the 5-HT1A receptor induced depression-like behavior in adulthood. By 
comparing the behavioral effects and changes in mRNA expression, we found that postnatal 
5-HT and the 5-HT1A receptor may decrease adult anxiety-like behavior by reducing the 
GABAA receptor α3 subunit in the ventral hippocampus in adulthood. On the other hand, the 
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5-HT1A receptor during the postnatal period may increase adult depression-like behavior by 
reducing the 5-HT1A receptor and BDNF in the mPFC and the GABAA receptor α2 subunit in 
the mPFC and ventral hippocampus in adulthood. Although the direct causal relationship 
between the gene expressions and the behaviors remain to be examined, the present study 
may provide a clue to understanding the mechanisms of anxiety and depression affected by 
5-HT and the 5-HT1A receptor during the postnatal period. 
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Table 
Table 1. Primer sequences for real-time reverse transcription-PCR 
Genes Primer sequences Tm (℃) Length 
5-HT1AR F: 5’-CCGTGAGAGGAAGACAGTGAAGAC-3’ 
R: 5’-GGTTGAGCAGGGAGTTGGAGTAG-3’ 
60.5 
62.2 
176 bp 
BDNF F: 5’-GACAAGGCAACTTGGCCTAC-3’ 
R: 5’-ACTGTCACACACGCTCAGCTC-3’ 
58.4 
60.4 
353 bp 
GABAARα2 F: 5’-GAGAATCGGTGCCAGCAAGAA-3’ 
R: 5’-CAGTCCATGGCAGTGGCATAA-3’ 
64.9 
64.2 
118 bp 
GABAARα3 F: 5’-TTTCAGGCCCAGTCACTTTGTTC-3’ 
R: 5’-TTCACACCTCATTACAACTGGCATC-3’ 
64.7 
64.4 
80 bp 
GluR1 F: 5’-AGCGGACAACCACCATCTCTG-3’ 
R: 5’-AAGGGTCGATTCTGGGATGTTTC-3’ 
64.8 
64.6 
80 bp 
GluR2 F: 5’-ATGGAACATTAGACTCTGGCTCCAC-3’ 
R: 5’-CTGCCGTAGTCCTCACAAACACA-3’ 
63.9 
64.6 
123 bp 
18S rRNA F: 5’-ACTCAACACGGGAAACCTC-3’ 
R: 5’-AACCAGACAAATCGCTCCAC-3’ 
56.1 
53.9 
123 bp 
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Figure 1 
Anxiety-like behavior in the elevated plus maze test  in mice treated with sucrose, 
fluoxetine, or 8-OH-DPAT from P1-P21. (A) Percentage of the time spent in the open 
arms. (B) Percentage of numbers of entries into open arms. (C) Total numbers of entries. 
Each bar represents the mean ± S.E.M (n=13 for control, n=14 for fluoxetine, n=14 for 
8-OH-DPAT). * p < 0.05, ** p < 0.01  
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Figure 2 
Depression-like behavior in the forced swim test in mice treated with sucrose, fluoxetine, 
or 8-OH-DPAT from P1-P21. (A) Floating time. (B) Swimming time. (C) Climbing time. 
Each bar represents the mean ± S.E.M (n=14 for control, n=13 for fluoxetine, n=13 for 
8-OH-DPAT). * p < 0.05 
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Figure 3 
Depression-like behavior in the sucrose preference test in mice treated with sucrose, 
fluoxetine, or 8-OH-DPAT from P1-P21. Each bar represents the mean ± S.E.M of 
sucrose preference (n=14 for control, n=13 for fluoxetine, n=14 for 8-OH-DPAT).  
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Figure 4  
The mRNA expression of the 5-HT1A receptor in the mPFC, amygdala, dorsal 
hippocampus, and ventral hippocampus in mice treated with sucrose, fluoxetine, or 8-
OH-DPAT from P1-P21. (A) The mRNA expression of the 5-HT1A receptor at P22. (B) 
The mRNA expression of the 5-HT1A receptor at P71. Each bar represents the mean ± 
S.E.M of latency (n=6~10 for each group). * p < 0.05, ** p < 0.01 
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Figure 5  
The mRNA expression of BDNF in the mPFC, amygdala, dorsal hippocampus, and 
ventral hippocampus in mice treated with sucrose, fluoxetine, or 8-OH-DPAT from P1-
P21. (A) The mRNA expression of BDNF at P22. (B) The mRNA expression of BDNF 
at P71. Each bar represents the mean ± S.E.M of latency (n=5~12 for each group). * p < 
0.05, ** p < 0.01, *** p < 0.001  
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Figure 6  
The mRNA expression of the GABAA receptor α2 and α3 subunits at P71 in the mPFC, 
amygdala, dorsal hippocampus, and ventral hippocampus in mice treated with sucrose, 
fluoxetine, or 8-OH-DPAT from P1-P21. (A) The mRNA expression of the GABAA 
receptor α2 subunit. (B) The mRNA expression of the GABAA receptor α3 subunit.  
Each bar represents the mean ± S.E.M of latency (n=5~10 for each group). * p < 0.05,  
** p < 0.01  
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Figure 7   
The mRNA expression of the GluR1 and GluR2 at P71 in the mPFC, dorsal 
hippocampus, and ventral hippocampus in mice treated with sucrose, fluoxetine, or 8-
OH-DPAT from P1-P21. (A) The mRNA expression of the GluR1. (B) The mRNA 
expression of the GluR2.  Each bar represents the mean ± S.E.M of latency (n=6~9 for 
each group). * p < 0.05 
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